{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:27Z","timestamp":1794978687626,"version":"4.9.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,2]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Bispecific antibodies binding CD3 and CLL-1 deplete CLL-1+ target cells in animal models. An appropriately engineered CLL-1\/CD3 bispecific antibody could be effective in treating AML.<\/jats:p>","DOI":"10.1182\/blood-2016-08-735365","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T22:20:29Z","timestamp":1480630829000},"page":"609-618","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":149,"title":["An anti-CD3\/anti\u2013CLL-1 bispecific antibody for the treatment of acute myeloid leukemia"],"prefix":"10.1182","volume":"129","author":[{"given":"Steven R.","family":"Leong","sequence":"first","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Sukumaran","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hristopoulos","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Totpal","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Stainton","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lu","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Wong","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Tam","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Newman","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Vuillemenot","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ellerman","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Gu","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Dennis","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zheng","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Zhang","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genee","family":"Lee","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Waye","family":"Chu","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney A.","family":"Prell","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedan","family":"Lin","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Laing","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Polson","sequence":"additional","affiliation":[{"name":"Research and Early Development, Genentech, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"31","key":"2019111905095488700_B1","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1200\/JCO.2014.57.1034","article-title":"The leukemias: a half-century of discovery","volume":"32","author":"Freireich","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111905095488700_B2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040620714532123","article-title":"The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond","volume":"5","author":"Wander","year":"2014","journal-title":"Ther Adv Hematol"},{"issue":"26","key":"2019111905095488700_B3","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2019111905095488700_B4","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111905095488700_B5","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111905095488700_B6","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"issue":"13","key":"2019111905095488700_B7","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2019111905095488700_B8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark Res"},{"issue":"22","key":"2019111905095488700_B9","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"2019111905095488700_B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cyto.b.20614","article-title":"Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up","volume":"82","author":"Larsen","year":"2012","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"2019111905095488700_B11","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111905095488700_B12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1634\/stemcells.2007-0861","article-title":"Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia","volume":"26","author":"Moshaver","year":"2008","journal-title":"Stem Cells"},{"issue":"6","key":"2019111905095488700_B13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10637-015-0289-4","article-title":"Blinatumomab for the treatment of acute lymphoblastic leukemia","volume":"33","author":"Kaplan","year":"2015","journal-title":"Invest New Drugs"},{"issue":"6","key":"2019111905095488700_B14","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/mp5007745","article-title":"An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer","volume":"12","author":"Leong","year":"2015","journal-title":"Mol Pharm"},{"issue":"1","key":"2019111905095488700_B15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1006\/jmbi.1997.1116","article-title":"Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library","volume":"270","author":"Atwell","year":"1997","journal-title":"J Mol Biol"},{"issue":"26","key":"2019111905095488700_B16","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"issue":"287","key":"2019111905095488700_B17","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"2019111905095488700_B18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood"},{"issue":"289","key":"2019111905095488700_B19","doi-asserted-by":"crossref","first-page":"289ra82","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci Transl Med"},{"issue":"15","key":"2019111905095488700_B20","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111905095488700_B21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111905095488700_B22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2567.2011.03458.x","article-title":"The immunological synapse: a cause or consequence of T-cell receptor triggering?","volume":"133","author":"Alarc\u00f3n","year":"2011","journal-title":"Immunology"},{"issue":"1","key":"2019111905095488700_B23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111905095488700_B24","doi-asserted-by":"crossref","first-page":"e0121546","DOI":"10.1371\/journal.pone.0121546","article-title":"A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans","volume":"10","author":"Gustafson","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2019111905095488700_B25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111905095488700_B26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/10245330701255163","article-title":"Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3\/TCR complex","volume":"12","author":"Ersvaer","year":"2007","journal-title":"Hematology"},{"issue":"2","key":"2019111905095488700_B27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"2019111905095488700_B28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","article-title":"T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment","volume":"8","author":"Schnorfeil","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2019111905095488700_B29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s00262-004-0505-0","article-title":"Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia","volume":"53","author":"Wendelbo","year":"2004","journal-title":"Cancer Immunol Immunother"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/5\/609\/1401518\/blood735365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/5\/609\/1401518\/blood735365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:10:10Z","timestamp":1574140210000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/5\/609\/36176\/An-antiCD3antiCLL1-bispecific-antibody-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,2,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-08-735365","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]}}}